SCHEMBL2863386

SCHEMBL2863386

O=C(Nc1ccnc2ccccc12)C1CNCC2C(=O)OC(c3ccccc3)(c3ccccc3)N12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.40
PTPN11 Q06124 1/20 0.40
SSTR4 P31391 3/20 0.36
NPSR1 Q6W5P4 1/20 0.36
S1PR1 P21453 2/20 0.35
S1PR3 Q99500 1/20 0.35
PLK4 O00444 1/20 0.35
CHEK1 O14757 1/20 0.35
PDPK1 O15530 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
CHEK2 O96017 1/20 0.35
CDK1 P06493 1/20 0.35
PIM1 P11309 1/20 0.35
RPS6KB1 P23443 1/20 0.35
CDK2 P24941 1/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35
CSNK1D P48730 1/20 0.35
CDK8 P49336 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2870952 0.95 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1HTTKDM4ELMNA
SCHEMBL2863081 0.85 KDM4E (0.43) NPSR1GSK3BSMN1; SMN2ALDH1A1KDM4E
SCHEMBL2869316 0.83 NPSR1 (0.35) NPSR1SMN1; SMN2KDM4E
SCHEMBL2862573 0.83 HCRTR2 (0.41) NPSR1SMN1; SMN2ALDH1A1HTT
SCHEMBL2861976 0.82 ALDH1A1 (0.40) NPSR1SMN1; SMN2ALDH1A1HTTHPGD
SCHEMBL2866128 0.81 STING1 (0.38) NPSR1SMN1; SMN2HTTKMT2A
SCHEMBL2863335 0.81 TNKS (0.46) NPSR1KDRSMN1; SMN2KDM4EKMT2A
SCHEMBL2861932 0.81 ALDH1A1 (0.39) NPSR1GSK3AGSK3BSMN1; SMN2ALDH1A1
SCHEMBL2867805 0.81 MAPT (0.39) NPSR1MAPK1
SCHEMBL2867440 0.80 EP300 (0.42) NPSR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 PTPN1 3290/4885PTPN11 2092/4885SSTR4 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.